NAPPA welcomes Dr. Joy Wang as Strategic Advisor
20+ years of portfolio strategy and Go/No-go decision experience across Novartis, Eli Lilly, Baxter, and Dendreon joins NAPPA's advisory bench.
NAPPA has appointed Dr. Joy Wang (PhD, MBA) as Strategic Advisor.
Dr. Wang brings 20+ years of leadership across the global biopharmaceutical industry, with senior roles at Novartis/Sandoz, Eli Lilly, Baxter, and Dendreon. Her expertise centers on portfolio strategy, global R&D synergy, and the design of Go/No-go decision frameworks — across neuroscience, oncology, and cell & gene therapy.
What this strengthens
Dr. Wang’s appointment deepens NAPPA’s strategic judgment and cross-regional transformation capabilities. In particular: portfolio prioritization at scale, early Go/No-go decisions on individual programs, and the strategic allocation of cross-border R&D investment across the U.S., China, and Asia-Pacific.